Page last updated: 2024-10-31

nafamostat and Pericarditis

nafamostat has been researched along with Pericarditis in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Pericarditis: Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hara, S1
Ubara, Y1

Reviews

1 review available for nafamostat and Pericarditis

ArticleYear
[Uremic pericarditis].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5

    Topics: Anticoagulants; Benzamidines; Cardiac Surgical Procedures; Death; Dialysis; Drainage; Glucocorticoid

2007